Current progress in detection of AD and other neurological disease depends on the presence of Aβ with or without tau or neurodegeneration in CNS and plasma biomarkers of disease [11, 12], although p-tau plasma biomarker, NF1 [13] and p-tau217 [14] show promise in longitudinal studies for early AD. This evidence concerns the gene MAPT and nervous system disorder.